Epilepsy Market Projected To Grow at a CAGR of ~3.5% during 2022 - 2031

(AmericaNewsHour via Comtex)

Research Nester published a report titled "Epilepsy Market: Global Demand Analysis & Opportunity Outlook 2031" which delivers detailed overview of the global epilepsy market in terms of market segmentation by treatment, end-user, and by region.

Further, for the in-depth analysis, the report encompasses the industry growth indicators, restraints, supply and demand risk, along with detailed discussion on current and future market trends that are associated with the growth of the market.

The global epilepsy market is anticipated to attain a CAGR of ~3.5% over the forecast period, i.e., 2022 - 2031. The market is segmented based on end-user into hospitals, clinics, ambulatory surgical centers, diagnostic centers, and others. Out of these, the hospitals segment is anticipated to hold a substantial share over the forecast period owing to the increasing patient pool of epilepsy, coupled with the availability of specialists in every field of medical science in hospitals.

The global epilepsy market is estimated to grow on the back of growing incidences of epilepsy across the globe. According to the data by the World Health Organization (WHO), around 50 million people worldwide have epilepsy. Moreover, the growing awareness about the disease and its treatment, along with declining taboo and stigma regarding epilepsy are further projected to encourage the market growth. Along with this, factors such as growing geriatric population, high healthcare expenditure, and advancement in medical science are expected to fuel the growth of the market.

Download Sample of This Strategic Report @ https://www.researchnester.com/sample-request-4084

On the basis of geographical analysis, the global epilepsy market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. The market in the North America region is anticipated to gain the largest market share throughout the forecast period, owing to the increasing prevalence of epilepsy, along with advanced healthcare facilities available in the region.

The research is global in nature and covers detailed analysis on the market in North America (U.S., Canada), Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC [Finland, Sweden, Norway, Denmark], Poland, Turkey, Russia, Rest of Europe), Latin America (Brazil, Mexico, Argentina, Rest of Latin America), Asia-Pacific (China, India, Japan, South Korea, Indonesia, Singapore, Malaysia, Australia, New Zealand, Rest of Asia-Pacific), Middle East and Africa (Israel, GCC [Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman], North Africa, South Africa, Rest of Middle East and Africa). In addition, analysis comprising market size, Y-O-Y growth & opportunity analysis, market players' competitive study, investment opportunities, demand for future outlook etc. has also been covered and displayed in the research report.

Curious about this latest version of report? Obtain Report Details @ https://www.researchnester.com/reports/epilepsy-market/4084

Increasing Demand for Treatment of Epilepsy to Boost the Market Growth

Decreased stigma regarding seizures of epilepsy is one of the major factors behind the surge in the adoption of epilepsy treatment amongst people. As the taboo is declining, people are demanding proper medications for the patients, which has resulted in higher awareness level amongst people globally. Such factors are anticipated to boost the market growth.   

However, limited accessibility to treatment in low- and middle-income countries is expected to operate as key restraint to the growth of global epilepsy market over the forecast period.

This report also provides the existing competitive scenario of some of the key players of the global epilepsy market which includes company profiling of Johnson & Johnson Services, Inc., Novartis AG, Stryker B.V., Pfizer, Inc., Sanofi aventis Group, Eisai Co. Ltd., Cephalon, Inc., Abbott Laboratories, Sunovion Pharmaceuticals, Inc, Koninklijke Philips N.V., The profiling enfolds key information of the companies which encompasses business overview, products and services, key financials and recent news and developments. On the whole, the report depicts detailed overview of the global epilepsy market that will help industry consultants, equipment manufacturers, existing players searching for expansion opportunities, new players searching possibilities and other stakeholders to align their market centric strategies according to the ongoing and expected trends in the future.   

Ask Industry Experts about this Report @ https://www.researchnester.com/sample-request-4084

About Research Nester

Research Nester is a leading service provider for strategic market research and consulting. We aim to provide unbiased, unparalleled market insights and industry analysis to help industries, conglomerates and executives to take wise decisions for their future marketing strategy, expansion and investment, etc. We believe every business can expand to its new horizon, provided a right guidance at a right time is available through strategic minds. Our out of box thinking helps our clients to take wise decision so as to avoid future uncertainties.

Contact Us

AJ Daniel
Email: [email protected]
U.S. Phone: [+1 646 586 9123]
U.K. Phone: [+44 203 608 591]

The post Epilepsy Market Projected To Grow at a CAGR of ~3.5% during 2022 - 2031 appeared first on America News Hour.

comtex tracking

COMTEX_409156612/2606/2022-06-24T04:38:56